Appeal Letter (Biologic/Targeted DMARD)

From: [Practice name], [Address], [Phone] | [Fax], [Clinician name and credentials], NPI: [NPI]

To: [Plan name], [UM/Appeals Department], [Fax/Address]

RE: [EXPEDITED / URGENT – if applicable] Appeal of denial for [Drug name (brand/generic)] – [Patient full name], DOB: [DOB], Member ID: [Member ID], Case/PA #: [Case/PA number], Denial date: [Denial date]

Request Type: [appeal/redetermination / formulary exception / step therapy override / quantity limit exception / site-of-care exception] | Review: [standard / expedited]

Executive Summary

[Medical necessity summary] (In 5–10 sentences, state: primary diagnosis and current severity; the requested bDMARD/tsDMARD with specific dose/route/frequency and why it is indicated now; key objective disease activity findings with dates and values; prior therapies tried with therapeutic duration and outcome or contraindications; and specific risks of harm if therapy is delayed. Write so a reviewer could approve without reading further.)

Clinical Background

[Disease course and phenotype overview] (1 short paragraph summarizing onset, progression, and phenotype elements that drive therapy choice.)

• Diagnosis: [Primary diagnosis] (ICD-10: [Code]) — [Phenotype details: axial/peripheral involvement, erosive disease, extra-articular manifestations, skin/nail involvement, uveitis, etc.]
• Disease Course: [Onset and trajectory], [flares/hospitalizations/surgeries], [erosions or structural damage], [steroid dependence], [persistently elevated inflammatory markers], [other severity modifiers]
• Relevant Comorbidities/Contraindications: [Serious infection history / malignancy / demyelinating disease / heart failure / hepatic disease / pregnancy considerations / other factors affecting agent selection] (Only include those that materially affect therapy safety or choice.)

Objective Disease Activity and Functional Status

(Present objective measures first, then brief interpretation. Use validated composite indices when available. If a composite score was not recorded, state this explicitly and provide objective substitutes.)

• Disease Activity Measure: [CDAI / SDAI / DAS28 / DAPSA / MDA / ASDAS / BASDAI / Mayo / HBI / fecal calprotectin / PASI / BSA / other validated instrument] — Value: [numeric], Date: [date], Category: [remission / low / moderate / high activity] (If not recorded, state: "No validated composite score recorded; objective substitutes provided below.")
• Examination Findings: [Date]: [Tender/swollen joint counts, enthesitis/dactylitis count, spinal mobility measures, synovitis on exam, physician global assessment] (Include only measured findings.)

Laboratory and Biomarkers

Date	Measure	Value/Result	Interpretation
[date]	[CRP / ESR / biomarker]	[value with units]	[elevated / normal / trend vs prior]

(Add rows as needed for relevant objective data.)

Imaging/Procedures

Date	Study	Key Finding	Interpretation
[date]	[Radiograph / Ultrasound / MRI / Endoscopy]	[Erosions / synovitis / sacroiliitis / endoscopic score]	[Progression vs prior / active inflammation]

(Include only if imaging/procedures were performed and findings are relevant to the appeal.)

Functional Impairment: [Work status and missed days], [ADL limitations: dressing, bathing, mobility, grip], [Validated function score if available: HAQ/MDHAQ/PROMIS with value and date], [Pain and fatigue severity with functional impact]

Prior Treatment History

(Document prior and current therapies at therapeutic doses with objective response and reasons for discontinuation. Use best available dates; indicate if chart-documented vs patient-reported.)

Drug	Dates	Dose/Frequency	Duration at Therapeutic Dose	Response	Reason Stopped
[csDMARD / bDMARD / tsDMARD / steroid]	[mm/yyyy–mm/yyyy]	[dose and route]	[duration]	[quantified response: score change, flare frequency, steroid-sparing outcome]	[inadequate response / adverse event (specify) / contraindication / other]

(Add rows for each relevant agent. If the denial cites a specific alternative, explain why that agent is contraindicated, expected to be less effective, or likely to cause adverse effects for this patient.)

Rationale for Requested Therapy

• Drug Requested: [Generic (Brand)], [formulation], [route], [dose], [frequency], [anticipated duration], [site of care: self-injection / clinic / outpatient infusion center / home infusion]
• Clinical Rationale: [Mechanism of action alignment with patient phenotype], [relevance to extra-articular/skin/gut involvement if applicable], [appropriateness given prior failures/intolerances], [patient-specific factors favoring this agent over alternatives]
• Safety and Monitoring: [Baseline screening completed/planned: TB, hepatitis B/C, HIV as indicated, vaccines], [lab monitoring plan], [response assessment plan and timeframe]
• Guideline Alignment: [FDA-labeled / off-label] for this diagnosis; aligned with [ACR / EULAR / GRAPPA / AGA / AAD / other] guidelines (If off-label, reference supporting guideline or peer-reviewed evidence in attachments.)

Response to Denial Rationale

(Quote each denial reason verbatim and respond directly with dated, objective evidence. Conclude each item with a single-sentence approval statement.)

1. Denial Reason #1: "[Verbatim quote of payer's stated reason, including policy name/criteria ID if provided]"

   Response: [Criterion met / not met / partially met]. [Specific supporting evidence: dates, values, measures, documented trials and durations, contraindications]. Therefore, [conclusion stating why coverage criteria are satisfied and approval is medically necessary].

2. Denial Reason #2: "[Verbatim quote]"

   Response: [As above with evidence and concluding statement].

(Add additional numbered items as needed. If denial letter is not available: "Denial rationale not provided; specific coverage criteria requested." Address the most likely requirements: step therapy completion, objective severity thresholds, formulary alternatives, dosing limits, site-of-care.)

Risk of Harm From Delay

[Patient-specific harms from delayed therapy] (Document current impairment: work disability, ADL limitations, steroid dependence, frequent flares. Note progressive findings: radiographic progression, organ involvement. State foreseeable harms: irreversible damage, hospitalization, surgery, steroid complications. If requesting expedited review, explicitly state that standard timeline risks serious harm with clinical justification.)

Requested Disposition

I am requesting overturn of the denial and authorization for [drug] at [dose/frequency] for [duration] with a start date of [requested start date]. Please contact me for a peer-to-peer discussion at [phone number] during [availability].

Attachments

[Denial letter], [Recent clinic notes], [Disease activity scores], [Laboratory reports], [Imaging/procedure reports], [Relevant guideline excerpts or peer-reviewed evidence], [Other supporting documentation] (List only attachments that are actually included.)

Attestation and Signature

I attest that the information provided is accurate and reflects the patient's medical record.

Signature: [Clinician name, credentials] | NPI: [NPI] | Date: [date]